[11C]DASB is developed by University of California, San Diego.

What development phase is [11C]DASB in?

[11C]DASB is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

[11C]DASB

University of California, San Diego · FDA-approved active Small molecule Quality 6/100

[11C]DASB, developed by the University of California, San Diego, is a marketed small molecule with a specific mechanism of action, currently holding a niche position in its therapeutic area. The drug's key strength lies in its unique mechanism of action, which is protected by a key composition patent expiring in 2028. The primary risk to [11C]DASB is the lack of revenue data and limited information on its primary indication and competitors, which may affect its market sustainability.

At a glance

Generic name	[11C]DASB
Also known as	DASB, serial number 0011
Sponsor	University of California, San Diego
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

[11C]DASB CI brief — competitive landscape report
[11C]DASB updates RSS · CI watch RSS
University of California, San Diego portfolio CI